Allogene Therapeutics annual ebitda
2018
2019
2020
2021
2022
2023
2024
2025
Allogene Therapeutics EBITDA Growth & History (ALLO)
Allogene Therapeutics's calculated EBITDA was −$197.0M for fiscal 2025.
View full Allogene Therapeutics company overviewAllogene Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$197.0M | $62.6M | — |
| 2024 | 2024-12-31 | −$259.6M | $54.0M | — |
| 2023 | 2023-12-31 | −$313.5M | $7.7M | — |
| 2022 | 2022-12-31 | −$321.2M | −$151.5M | — |
| 2021 | 2021-12-31 | −$169.7M | $81.2M | — |
| 2020 | 2020-12-31 | −$250.8M | −$53.4M | — |
| 2019 | 2019-12-31 | −$197.4M | −$5.6M | — |
| 2018 | 2018-12-31 | −$191.8M | — | — |
Allogene Therapeutics quarterly ebitda
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$44.3M | $9.4M | — |
| Q1 2026 | 2026-03-31 | −$43.2M | $18.9M | — |
| Q4 2025 | 2025-12-31 | −$39.3M | $17.9M | — |
| Q3 2025 | 2025-09-30 | −$41.8M | $26.8M | — |
| Q2 2025 | 2025-06-30 | −$53.7M | $14.1M | — |
| Q1 2025 | 2025-03-31 | −$62.1M | $3.9M | — |
| Q4 2024 | 2024-12-31 | −$57.3M | $2.2M | — |
| Q3 2024 | 2024-09-30 | −$68.6M | −$74.6M | — |
| Q2 2024 | 2024-06-30 | −$67.8M | $7.6M | — |
| Q1 2024 | 2024-03-31 | −$65.9M | $3.1M | — |
| Q3 2023 | 2023-09-30 | −$59.4M | −$28.1M | — |
| Q4 2021 | 2021-12-31 | $6.0M | $73.7M | — |
| Q3 2021 | 2021-09-30 | −$75.3M | −$9.1M | — |
| Q2 2021 | 2021-06-30 | −$69.1M | −$7.8M | — |
| Q1 2021 | 2021-03-31 | −$31.3M | $24.4M | — |
| Q4 2020 | 2020-12-31 | −$67.7M | −$5.0M | — |
| Q3 2020 | 2020-09-30 | −$66.2M | −$12.4M | — |
| Q2 2020 | 2020-06-30 | −$61.3M | −$16.3M | — |
| Q1 2020 | 2020-03-31 | −$55.6M | −$19.7M | — |
| Q4 2019 | 2019-12-31 | −$62.7M | −$30.0M | — |
| Q3 2019 | 2019-09-30 | −$53.8M | −$32.0M | — |
| Q2 2019 | 2019-06-30 | −$45.0M | $89.8M | — |
| Q1 2019 | 2019-03-31 | −$35.9M | −$33.3M | — |
| Q4 2018 | 2018-12-31 | −$32.7M | — | — |
| Q3 2018 | 2018-09-30 | −$21.8M | — | — |
| Q2 2018 | 2018-06-30 | −$134.7M | — | — |
| Q1 2018 | 2018-03-31 | −$2.6M | — | — |
Allogene Therapeutics ebitda trends
Over the last five reported fiscal years, Allogene Therapeutics's ebitda increased from −$250.8M to −$197.0M, a change of $53.9M. The latest reported quarter, Q2 2026, shows −$44.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Allogene Therapeutics filings at SEC.gov ↗